Test Price
2,800 AEDโ Home Collection Available
NPHS1 Gene Nephrosis, Finnish Type Genetic Test in UAE | 2,800 AED | DHA-Approved Molecular Diagnostics
Executive Summary โ Diagnostic Excellence, UAE-Compliant
- โ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via NGS (Next-Generation Sequencing) processed in ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139).
- โ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection โ Available daily from 8 AM to 11 PM, 7 Days.
- โ Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation by DHA-Licensed Physicians.
- โ Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The NPHS1 Gene Nephrosis, Finnish Type Genetic Test is a comprehensive molecular diagnostic assay designed to detect pathogenic mutations in the NPHS1 gene encoding nephrin โ a critical slit-diaphragm protein essential for glomerular filtration integrity. This test is indicated for patients presenting with congenital nephrotic syndrome, unexplained proteinuria in infancy, or a positive family history suggestive of autosomal recessive nephropathy. Sequencing is performed on an Illumina NGS platform achieving 100x mean depth with orthogonal validation by Sanger sequencing for all reported variants.
| Feature | Our Test โ NGS Full Gene Sequencing | Closest Alternative โ Targeted Sanger Sequencing |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity; full coding region + splice sites | ~95% for targeted exons only; misses deep intronic & novel variants |
| Methodology | NGS (Illumina Platform, 100x Mean Depth) with Sanger Validation | Capillary Sanger Sequencing, single-amplicon resolution |
| Turnaround Time | 3 to 4 Weeks (21โ28 Days) | 6 to 8 Weeks for full gene coverage |
| Variant Detection | SNVs, Indels, CNVs, and Splice-Altering Variants | SNVs and small Indels in targeted regions only |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (DHA Registration ID: 9294403): As a Consultant Medical Genetics practising in the UAE, I have observed that early molecular diagnosis of congenital nephrotic syndrome of the Finnish type through NPHS1 sequencing can fundamentally alter clinical outcomes. Identifying biallelic NPHS1 mutations allows for timely initiation of albumin replacement therapy, optimisation of nutritional support, and appropriate referral for renal transplantation evaluation. I advise all families undergoing this testing to participate in comprehensive pre- and post-test genetic counselling to fully understand the implications of results, including recurrence risks and carrier status for extended family members. All molecular findings must be interpreted alongside clinical presentation, renal biopsy histology where indicated, and serum biochemical markers to construct a complete clinical picture.
Critical Medication Advisory
Do not discontinue prescribed medication โ including corticosteroids, diuretics, albumin infusions, or immunosuppressive therapy โ without consulting your supervising physician. This genetic test is diagnostic in nature and does not replace ongoing clinical management or alter existing medication regimens. Always maintain your current treatment schedule until explicitly advised otherwise by your treating doctor.
Safety Protocol โ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Home Collection:
- Current acute febrile illness (temperature โฅ38.5ยฐC) โ reschedule after recovery
- Known bleeding diathesis or severe thrombocytopenia (platelets <50,000/ยตL) without physician clearance
- Inability to provide valid informed consent (patient or legal guardian per Federal Decree-Law No. 4 of 2016 on Medical Liability)
- Recent blood transfusion within 14 days (may affect germline DNA interpretation)
Emergency Red Flags โ Seek Immediate Medical Attention:
- Sudden anasarca (generalised oedema) with respiratory distress
- Oliguria (<0.5 mL/kg/hour for >6 hours) or anuria
- Severe hypertension (systolic >160 mmHg in infants/children)
- Signs of spontaneous bacterial peritonitis or sepsis
Patient FAQ & Clinical Guidance
1. What is the NPHS1 gene Finnish type nephrosis test and what does it diagnose?
The NPHS1 Genetic Test identifies pathogenic mutations in the NPHS1 gene responsible for congenital nephrotic syndrome of the Finnish type, enabling definitive molecular diagnosis and guiding clinical management decisions. This test sequences the entire coding region of the NPHS1 gene โ which encodes the nephrin protein essential for kidney filtration โ to detect single nucleotide variants, small insertions and deletions, copy number variations, and splice-altering mutations. Congenital nephrotic syndrome of the Finnish type is an autosomal recessive disorder most prevalent in Finnish populations but increasingly recognised in Middle Eastern and UAE cohorts. Early diagnosis through this test enables timely nephrology referral, albumin replacement strategies, and informed pre-transplant evaluation.
2. Who should consider undergoing this NPHS1 genetic test in the UAE?
Individuals with a family history of congenital nephrotic syndrome, infants presenting with unexplained proteinuria or oedema, and couples with known consanguinity planning pregnancy should consider this NPHS1 genetic test for accurate risk assessment. The test is also indicated for siblings of affected probands, pre-conception carrier screening in high-risk families, and individuals of Finnish descent exhibiting nephrotic-range proteinuria. In the UAE context, where autosomal recessive conditions are more prevalent due to cultural and demographic factors, proactive carrier screening is increasingly recommended. A pre-test genetic counselling session โ included in our service protocol โ helps draw a comprehensive pedigree chart and ensures fully informed decision-making.
3. How long do results take and how should I interpret my NPHS1 test report?
Results are delivered within 3 to 4 weeks (21โ28 days), and every report includes a clinically annotated interpretation classifying variants as pathogenic, likely pathogenic, or of uncertain significance per ACMG guidelines. Your DHA-certified report will detail the specific NPHS1 mutation(s) identified, zygosity status (homozygous or compound heterozygous), and a clear correlation with the Finnish-type congenital nephrotic syndrome phenotype where applicable. Post-test telephonic guidance with a DHA-licensed physician is included to walk you through the implications โ including prognosis, recommended specialist referrals (nephrologist, clinical geneticist), and family cascade testing options. Results are delivered securely via our encrypted patient portal in compliance with UAE data privacy regulations.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Privacy Framework
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) ensuring that all genetic data is processed, stored, and transmitted under strict confidentiality and security controls. All health information handling adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, which governs the electronic exchange of medical records and telehealth communications. Clinical safety and patient consent protocols are aligned with Federal Decree-Law No. 4 of 2016 on Medical Liability, which sets the standards for informed consent, professional medical accountability, and patient rights across UAE healthcare facilities. Our laboratory is ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) and holds DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | NPHS1 Gene Nephrosis, Finnish Type Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks (21โ28 Days) |
| Sample Type / Matrix | Peripheral Whole Blood (DNA Extraction) โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available |
| Methodology Used | NGS (Illumina Platform, 100x Mean Depth) with Sanger Orthogonal Validation |
| ICD-10-CM Code | N04.9, Z15.89 |
| LOINC Code | 95208-4 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians